Leaflet DOXAZOSIN/FINASTERIDA MIP 4mg / 5mg film-coated tablets


Indicated for: hypertension

Substance: doxazosin + finasteride (alpha-1 blocker + enzyme inhibitor)

ATC: G04CA55 (Genito urinary system and sex hormones | Drugs used in benign prostatic hypertrophy | Alpha-adrenoreceptor antagonists)

The combination of doxazosin and finasteride is used for the treatment of moderate to severe symptoms of benign prostatic hyperplasia. Doxazosin relaxes the smooth muscles in the prostate and bladder, while finasteride reduces prostate size by inhibiting the conversion of testosterone to dihydrotestosterone.

The medication is taken orally, as directed by a doctor, usually once daily. It is important to follow the treatment duration to achieve maximum benefits.

Side effects may include dizziness, decreased libido, erectile dysfunction, or orthostatic hypotension. In rare cases, severe allergic reactions or gynecomastia may occur.

This combination is not recommended for patients with hypersensitivity to any of the components or severe hepatic impairment.

General data about DOXAZOSIN/FINASTERIDA MIP 4mg / 5mg

  • Substance: doxazosin + finasteride
  • Date of last drug list: 01-06-2025
  • Commercial code: W71100001
  • Concentration: 4mg / 5mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 10
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: MIP PHARMA GMBH - GERMANIA
  • Holder: MIP PHARMA GMBH - GERMANIA
  • Number: 16003/2025/01
  • Shelf life: 3 years